Gluskin Sheff & Assoc Inc. Invests $4.32 Million in Eli Lilly and Company (NYSE:LLY)

Gluskin Sheff & Assoc Inc. purchased a new position in Eli Lilly and Company (NYSE:LLYGet Rating) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,072 shares of the company’s stock, valued at approximately $4,316,000.

Several other institutional investors have also recently made changes to their positions in the company. Guardian Wealth Advisors LLC NC bought a new position in shares of Eli Lilly and in the first quarter worth $260,000. 1832 Asset Management L.P. increased its stake in Eli Lilly and by 2,999.1% in the first quarter. 1832 Asset Management L.P. now owns 1,621,696 shares of the company’s stock valued at $458,118,000 after acquiring an additional 1,569,368 shares during the last quarter. Power Corp of Canada bought a new position in Eli Lilly and in the first quarter valued at $1,648,000. Journey Strategic Wealth LLC increased its stake in Eli Lilly and by 2.3% in the first quarter. Journey Strategic Wealth LLC now owns 1,673 shares of the company’s stock valued at $479,000 after acquiring an additional 37 shares during the last quarter. Finally, Cable Hill Partners LLC increased its stake in Eli Lilly and by 4.3% in the first quarter. Cable Hill Partners LLC now owns 12,305 shares of the company’s stock valued at $3,524,000 after acquiring an additional 502 shares during the last quarter. Institutional investors own 82.45% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and news, SVP Alonzo Weems sold 656 shares of the firm’s stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total value of $199,752.00. Following the completion of the sale, the senior vice president now directly owns 8,136 shares in the company, valued at $2,477,412. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Eli Lilly and news, SVP Alonzo Weems sold 656 shares of the firm’s stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total value of $199,752.00. Following the completion of the sale, the senior vice president now directly owns 8,136 shares in the company, valued at $2,477,412. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 22nd. The shares were sold at an average price of $306.84, for a total transaction of $64,436,400.00. Following the transaction, the insider now directly owns 104,623,810 shares of the company’s stock, valued at approximately $32,102,769,860.40. The disclosure for this sale can be found here. Insiders sold 753,125 shares of company stock worth $242,744,201 over the last three months. Company insiders own 0.12% of the company’s stock.

Analysts Set New Price Targets

LLY has been the topic of a number of research analyst reports. StockNews.com cut Eli Lilly and from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 5th. Morgan Stanley increased their target price on Eli Lilly and from $395.00 to $412.00 and gave the company an “overweight” rating in a research note on Wednesday, September 7th. Citigroup increased their target price on Eli Lilly and from $285.00 to $370.00 in a research note on Thursday, August 25th. BMO Capital Markets upped their price target on shares of Eli Lilly and from $369.00 to $396.00 and gave the company an “outperform” rating in a research report on Tuesday, September 6th. Finally, SVB Leerink initiated coverage on shares of Eli Lilly and in a research report on Monday, May 23rd. They set an “outperform” rating and a $341.00 price target for the company. Three analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $330.44.

Eli Lilly and Stock Performance

Eli Lilly and stock opened at $315.22 on Tuesday. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 1.70. The firm has a 50-day moving average of $317.94 and a 200-day moving average of $301.86. The firm has a market cap of $299.51 billion, a P/E ratio of 50.27, a P/E/G ratio of 2.16 and a beta of 0.38. Eli Lilly and Company has a 1-year low of $220.20 and a 1-year high of $335.33.

Eli Lilly and (NYSE:LLYGet Rating) last issued its quarterly earnings data on Thursday, August 4th. The company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.86 by ($0.61). Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. The company had revenue of $6.49 billion during the quarter, compared to analysts’ expectations of $6.85 billion. During the same quarter last year, the business earned $1.87 earnings per share. The business’s quarterly revenue was down 3.7% on a year-over-year basis. Sell-side analysts expect that Eli Lilly and Company will post 7.97 EPS for the current year.

Eli Lilly and Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 9th. Shareholders of record on Monday, August 15th were issued a $0.98 dividend. The ex-dividend date was Friday, August 12th. This represents a $3.92 annualized dividend and a yield of 1.24%. Eli Lilly and’s dividend payout ratio (DPR) is presently 62.52%.

Eli Lilly and Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Read More

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.